Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Biolinq Incorporated manages a patent portfolio in the Medical Devices & Mechanical Engineering technology area with 5 pending office actions. These actions are distributed among 5 distinct examiners, showing a broad engagement across different individuals at the patent office. The prosecution activity spans 3 distinct art units, which indicates that the company's technology is being reviewed across several specialized technical groups. This distribution across 3 units suggests that the innovations touch upon multiple sub-specialties within the Medical Devices & Mechanical Engineering sector.
KRETZER, KYLE W. is identified as the busiest examiner for the company, currently holding 1 pending office action. This means that while KRETZER, KYLE W. is the busiest, the workload is evenly distributed, as each of the 5 distinct examiners is likely handling 1 of the 5 pending actions. This distribution suggests that no single examiner has a dominant influence over the entire pending portfolio. For practitioners, this requires navigating the different standards and practices of 5 separate examiners, which may lead to varying prosecution timelines and outcomes.
The 5 to 5 ratio of pending actions to examiners further emphasizes a diverse prosecution landscape where each application is facing a unique set of examiner expectations. Practitioners should be prepared to manage multiple examiner relationships simultaneously, as the data shows no concentration of actions under a single official. The involvement of 3 distinct art units adds another layer of complexity, as each unit may have its own internal guidelines and examination culture. This profile represents a decentralized prosecution environment for the company's current intellectual property assets.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRETZER, KYLE W. | 1 | 64.8% | +41.5% |
| TOMBERS, JOSEPH A | 1 | 49.8% | +32.1% |
| VASSELL, MEREDITH ABBOTT | 1 | 30.3% | +47.0% |
| CHUNG, HOSUNG CHARLES | 1 | 59.1% | +38.3% |
| HOFFPAUIR, ANDREW ELI | 1 | 41.4% | +52.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634420 | INTEROPERABILITY AND DATA EXCHANGE CAPABILITIES BETWEEN A BLOOD GLUCOSE MONITOR AND A CONTINUOUS GLUCOSE MONITOR | TOMBERS, JOSEPH A | 34d |
| 18830480 | DEVICES AND METHODS FOR THE MITIGATION OF NON-ANALYTE SIGNAL PERTURBATIONS INCIDENT UPON ANALYTE-SELECTIVE SENSOR | KRETZER, KYLE W. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18243623 | HEALTH-RELATED SIGNALING VIA WEARABLE ITEMS | VASSELL, MEREDITH ABBOTT | 85d overdue |
| 18634420 | INTEROPERABILITY AND DATA EXCHANGE CAPABILITIES BETWEEN A BLOOD GLUCOSE MONITOR AND A CONTINUOUS GLUCOSE MONITOR | TOMBERS, JOSEPH A | 34d |
| 18830480 | DEVICES AND METHODS FOR THE MITIGATION OF NON-ANALYTE SIGNAL PERTURBATIONS INCIDENT UPON ANALYTE-SELECTIVE SENSOR | KRETZER, KYLE W. | — |
| 17850832 | TISSUE-PENETRATING ELECTROCHEMICAL SENSOR FEATURING A CO-ELECTRODEPOSITED THIN FILM COMPRISED OF POLYMER AND BIO-RECOGNITION ELEMENT | CHUNG, HOSUNG CHARLES | — |
| 17348651 | Devices and Methods For Application Of Microneedle Arrays Using Radial And Axial Accelerations | HOFFPAUIR, ANDREW ELI | — |
| Art Unit | Apps |
|---|---|
| 3791 | 2 |
| 1687 | 1 |
| 1794 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18830480 | DEVICES AND METHODS FOR THE MITIGATION OF NON-ANALYTE SIGNAL PERTURBATIONS INCIDENT UPON ANALYTE-SELECTIVE SENSOR | KRETZER, KYLE W. | — | §101§103 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18634420 | INTEROPERABILITY AND DATA EXCHANGE CAPABILITIES BETWEEN A BLOOD GLUCOSE MONITOR AND A CONTINUOUS GLUCOSE MONITOR | TOMBERS, JOSEPH A | 3791 | §101§102§103 | Non-Final OA | 34d | Pending | Apr 12, 2024 |
| 18243623 | HEALTH-RELATED SIGNALING VIA WEARABLE ITEMS | VASSELL, MEREDITH ABBOTT | 1687 | §112DP | Final Rejection | 85d overdue | Pending | Sep 07, 2023 |
| 17850832 | TISSUE-PENETRATING ELECTROCHEMICAL SENSOR FEATURING A CO-ELECTRODEPOSITED THIN FILM COMPRISED OF POLYMER AND BIO-RECOGNITION ELEMENT | CHUNG, HOSUNG CHARLES | 1794 | §102§103§112DP | Non-Final OA | — | Pending | Jun 27, 2022 |
| 17348651 | Devices and Methods For Application Of Microneedle Arrays Using Radial And Axial Accelerations | HOFFPAUIR, ANDREW ELI | 3791 | §103 | Final Rejection | — | Pending | Jun 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial